Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.72 |
| ▸ | CTSK | P43235 | 6/20 | 0.72 |
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.62 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 5/20 | 0.54 |
| ▸ | PPARG | P37231 | 4/20 | 0.54 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
| ▸ | FPR2 | P25090 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26271 | 1.00 | CTSS (0.72) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL763600 | 1.00 | CTSS (0.72) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL21447323 | 0.89 | CTSS (0.69) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL16448051 | 0.89 | ACE (0.62) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL25532536 | 0.89 | CTSS (0.68) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL5887611 | 0.89 | CTSS (0.68) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL5887609 | 0.89 | CTSS (0.68) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL11728465 | 0.89 | CTSS (0.61) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL2617401 | 0.88 | CTSS (0.67) | CTSSCTSKACEITGB3ITGA2B | |
| SCHEMBL539218 | 0.88 | CTSS (0.67) | CTSSCTSKACEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574245-A | 4-10Preparation method of boric acid group-L-phenylalanine | 四川瑶天纳米科技有限责任公司 | 2021-03-30 | — | — | CN | claimed |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| WO-2025128805-A1 | A CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2025-05-15 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-1404324-A4 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6818787-B2 | FOR THERAPY AND PROPHYLAXIS OF EPILEPSY, DEPRESSION, ANXIETY, PSYCHOSIS, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, PANIC, PAIN, INFLAMMATORY DISEASE, INSOMNIA, GASTROINTESTINAL DISORDERS | XENOPORT, INC. | 2004-11-16 | — | — | US | disclosed |
| WO-2004052844-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004046091-A2 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-03 | — | — | WO | disclosed |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | XENOPORT, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1404324-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040006132-A1 | Prodrugs of gaba analogs, compositions and uses thereof | ARBOR PHARMACEUTICALS, LLC | 2004-01-08 | — | — | US | disclosed |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2003-09-18 | — | — | US | disclosed |
| WO-2002100347-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| CN-1288457-A | Inhibitors of & alpha, 4 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2001-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | CTSS 3911/4885CTSK 3172/4885ACE 457/4885 |
| US-20040077553-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | CTSS 2244/4885CTSK 2845/4885ACE 977/4885 |
| US-20040006132-A1 | Prodrugs of gaba analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | CTSS 2244/4885CTSK 2845/4885ACE 977/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | CTSS 565/4885CTSK 868/4885ACE 3189/4885 |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | CTSS 640/4885CTSK 1101/4885ACE 1331/4885 |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | CTSS 2244/4885CTSK 2845/4885ACE 977/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | CTSS 4675/4885CTSK 4419/4885ACE 1529/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | CTSS 112/4885CTSK 151/4885ACE 158/4885 |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | IL1R1, IL1A, IL1B | CTSS 1403/4885CTSK 1280/4885ACE 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.